Alpha Cognition Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Alpha Cognition Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative diseases, with an emphasis on Alzheimer’s disease and cognitive impairment linked to mild traumatic brain injury. The company’s portfolio includes ZUNVEYL, an oral therapy marketed for mild-to-moderate Alzheimer’s disease, alongside additional programs in development that explore alternative formulations and combination approaches for broader dementia-related needs. Alpha Cognition also works on research programs targeting amyotrophic lateral sclerosis and other neurodegenerative conditions. Based in Vancouver, Canada, the company operates in the neuroscience and biotechnology markets, addressing areas where treatment options remain limited and clinical need is high.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Michael E. McFadden B.B.A.
- Employees
- 71
- Headquarters
- Grapevine, TX, United States
- Website
- www.alphacognition.com